Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

The shingles vaccine is recommended for healthy adults age 50 or older, and also for anyone age 19 years or older who has a ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

This article discusses what you need to know about Shingrix, the shingles vaccine. Getting vaccinated is the best way to prevent shingles and postherpetic neuralgia (PHN). It’s estimated that up ...

Shingrix, the new shingles vaccine, is over 90 percent effective in preventing the painful viral infection Julie Mazziotta is the Senior Sports Editor at PEOPLE, covering everything from the NFL ...

Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's Tal Zaks to board. Aims to compete with GSK's Shingrix.

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance ...